Gossamer Bio Unveils New Clinical Insights into Seralutinib's Efficacy for Pulmonary Hypertension at ERS Congress 2025
Gossamer Bio Inc., a clinical-stage biopharmaceutical company, has announced that it will present five scientific presentations related to its drug seralutinib at the upcoming European Respiratory Society (ERS) Congress 2025. The presentations will focus on seralutinib's potential in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The ERS Congress will take place from September 27th to October 1st, 2025, in Amsterdam, Netherlands, and online. The presentations will include both oral and poster sessions, highlighting seralutinib's effects on fibrotic pathways, anti-fibrotic effects, and impact on vascular inflammatory drivers. These presentations have not yet been made and are scheduled to occur at the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922224756) on September 22, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。